Substituted derivatives of isoindoles
AssigneeSupernus Pharmaceuticals, Inc.
InventorsGary L. Olson, Bhaskara Rao Nallaganchu, Yanjun Sun
Life of this patent
Estimating the term…
Abstract
Substituted derivatives of 5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol and their uses in pharmaceutical compositions for the treatment of central nervous system diseases or disorders are provided.
Claims36
An isoindoline derivative of Formula I, or a stereoisomer or a pharmaceutically acceptable salt thereof:
- wherein:
- R1 is an alkyl group, an alkenyl group, an aralkyl group, an alkoxyalkyl group, a carboxyalkyl ester group, a cinnamyl group, a heteroalkyl group or a heterocycloalkyl group;
- and
- R2-R5 are each independently H or alkyl;
- and
- R6-R14 are each independently H, alkyl, alkoxy, F, Cl, Br, CF3 or I, wherein the isoindoline derivative is not of formula I-6:
An isoindoline derivative of Formula II, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
- wherein:
- R1 is a piperazinyl group, an alkyl group, an alkenyl group, a benzyl group, a phenyl group, or an amino acid residue derivative;
- and
- R2-R14 are each independently H, F, Cl, Br, or I.
A dimeric isoindoline derivative of Formula III, a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
- wherein:
- R1 is an alkyl group, an alkenyl group, an aryl group, or a heteroaryl group;
- and
- R2-R14 are each independently H, F, Cl, Br, or I.
A method for treating a central nervous system disorder in a mammal, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, II, or III, or a stereoisomer thereof, or a pharmaceutically acceptable salt thereof:
- wherein:
- for Formula I, R1 is an alkyl group, an alkenyl group, an aralkyl group, an alkoxyalkyl group, a carboxyalkyl ester group, a cinnamyl group, a heteroalkyl group or a heterocycloalkyl group;
- R2-R5 are each independently H or alkyl;
- and R6-R14 are each independently H, alkyl, alkoxy, F, Cl, Br, CF3 or I;
- for Formula II, R1 is a piperazinyl group, an alkyl group, an alkenyl group, a benzyl group, a phenyl group, or an amino acid residue derivative;
- and R2-R14 are each independently H, F, Cl, Br, or I;
- and
- for Formula III, R1 is an alkyl group, an alkenyl group, an aryl group, or a heteroaryl group;
- and R2-R14 are each independently H, F, Cl, Br, or I.
(canceled)
A method of making an isoindoline derivative of Formula I, II, or III, by contacting Compound A (5-(4-chlorophenyl)-2,3-dihydroimidazo[1,2-b]isoindol-5-ol) or a pharmaceutically acceptable salt thereof, with a reactive compound suitable for forming the derivative of Formula I, II, or III, wherein
- for Formula I, R1 is an alkyl group, an alkenyl group, an aralkyl group, an alkoxyalkyl group, a carboxyalkyl ester group, a cinnamyl group, a heteroalkyl group or a heterocycloalkyl group;
- R2-R5 are each independently H or alkyl;
- and R6-R14 are each independently H, alkyl, alkoxy, F, Cl, Br, CF3 or I;
- for Formula II, R1 is a piperazinyl group, an alkyl group, an alkenyl group, a benzyl group, a phenyl group, or an amino acid residue derivative;
- and R2-R14 are each independently H, F, Cl, Br, or I;
- and
- for Formula III, R1 is an alkyl group, an alkenyl group, an aryl group, or a heteroaryl group;
- and R2-R14 are each independently H, F, Cl, Br, or I.
Dependencies are inferred from the claim text.